AR122660A2 - ANTI-PMEL17 ANTIBODIES AND CONJUGATES THEREOF - Google Patents

ANTI-PMEL17 ANTIBODIES AND CONJUGATES THEREOF

Info

Publication number
AR122660A2
AR122660A2 ARP210101664A ARP210101664A AR122660A2 AR 122660 A2 AR122660 A2 AR 122660A2 AR P210101664 A ARP210101664 A AR P210101664A AR P210101664 A ARP210101664 A AR P210101664A AR 122660 A2 AR122660 A2 AR 122660A2
Authority
AR
Argentina
Prior art keywords
antibodies
antigen
binding fragments
antibody
methods
Prior art date
Application number
ARP210101664A
Other languages
Spanish (es)
Inventor
Matthew Burger
Joseph Anthony Dalessio
Tony Fleming
Vivek Rauniyar
Robles Eusebio Manchado
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR122660A2 publication Critical patent/AR122660A2/en

Links

Abstract

La presente solicitud describe anticuerpos anti-PMEL17, fragmentos de unión a antígeno de los mismos, y conjugados de anticuerpo fármaco de dichos anticuerpos o fragmentos de unión a antígeno conjugados a un inhibidor de GNAQ / GNA11. La invención además se refiere a métodos para tratar o prevenir el cáncer usando los anticuerpos, fragmentos de unión a antígeno, y conjugados de anticuerpo fármaco. Además se describen métodos de preparación de anticuerpos, fragmentos de unión a antígeno, y conjugados de anticuerpo fármaco, y métodos de uso de los anticuerpos y fragmentos de unión a antígeno como reactivos de diagnóstico.The present application describes anti-PMEL17 antibodies, antigen-binding fragments thereof, and antibody-drug conjugates of such antibodies or antigen-binding fragments conjugated to a GNAQ/GNA11 inhibitor. The invention further relates to methods of treating or preventing cancer using the antibodies, antigen-binding fragments, and antibody-drug conjugates. Also described are methods of preparing antibodies, antigen-binding fragments, and antibody-drug conjugates, and methods of using the antibodies and antigen-binding fragments as diagnostic reagents.

ARP210101664A 2018-12-21 2021-06-17 ANTI-PMEL17 ANTIBODIES AND CONJUGATES THEREOF AR122660A2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862783565P 2018-12-21 2018-12-21

Publications (1)

Publication Number Publication Date
AR122660A2 true AR122660A2 (en) 2022-09-28

Family

ID=77568195

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP190103765A AR117446A1 (en) 2018-12-21 2019-12-19 ANTI-PMEL17 ANTIBODIES AND CONJUGATES THEREOF
ARP210101664A AR122660A2 (en) 2018-12-21 2021-06-17 ANTI-PMEL17 ANTIBODIES AND CONJUGATES THEREOF

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP190103765A AR117446A1 (en) 2018-12-21 2019-12-19 ANTI-PMEL17 ANTIBODIES AND CONJUGATES THEREOF

Country Status (1)

Country Link
AR (2) AR117446A1 (en)

Also Published As

Publication number Publication date
AR117446A1 (en) 2021-08-04

Similar Documents

Publication Publication Date Title
CO2017004782A2 (en) Antibody-drug conjugates
CL2021001607A1 (en) Anti-pmel17 antibodies and conjugates thereof
CR20190346A (en) Anti-ccr7 antibody drug conjugates
CL2020003071A1 (en) Multispecific binding proteins and enhancements with them
BR112018006016A2 (en) binder-drug intermediate, antibody-drug conjugate compounds, pharmaceutical compositions, methods for treating cancer, method of producing an antibody-drug conjugate and conjugate
CO2022002622A2 (en) Anti-cd73 antibodies and compositions
CO2022009696A2 (en) Anti-lilrb1 antibody and uses thereof
BR112018072118A2 (en) interferon beta antibodies and their uses
CL2021001593A1 (en) Tubulisins and protein-tubulisin conjugates
BR112021025720A2 (en) Antitissue factor antibody-drug conjugates and related methods
CO2022002573A2 (en) Antibodies against ilt2 and their use
WO2018089807A3 (en) Anti-cd46 antibodies and methods of use
BR112021016596A2 (en) Anti-pd-l1 antibody and its use
CL2021003215A1 (en) Anti-pcrv antibodies that bind to pcrv, compositions comprising anti-pcrv antibodies, and methods of using these
CO2023002375A2 (en) Antibodies against ilt2 and use thereof
BR112022008756A2 (en) ANTI-MESOTHELIN ERIBULIN ANTIBODY-DRUG CONJUGATES AND METHODS OF USE
EA201992315A1 (en) COMPOSITIONS AND METHODS FOR TREATING LUNG CANCER
BR112022009672A2 (en) TREATMENT OF CANCER WITH ANTIBODY-DRUG CONJUGATES (ADC) THAT BIND TO 191P4D12 PROTEINS
AR122660A2 (en) ANTI-PMEL17 ANTIBODIES AND CONJUGATES THEREOF
MX2020003806A (en) Dna monoclonal antibodies targeting ctla-4 for the treatment and prevention of cancer.
CL2022001937A1 (en) Anti-pmel17 antibodies and conjugates thereof (divisional 202101607)
EA202192173A1 (en) ANTI-CD228 ANTIBODIES AND ANTIBODY-DRUG CONJUGATES
AR115987A1 (en) ANTI-GDF15 ANTIBODIES, COMPOSITIONS AND METHODS OF USE
AR118787A1 (en) PD-L1 BINDING MOLECULES AND USE THEREOF FOR THE TREATMENT OF DISEASES
AR121317A2 (en) ANTI-HTRA1 ANTIBODIES AND METHODS OF USE THEREOF